Show Summary Details
Page of

Osteoporosis and SREs in neoplastic disease 

Osteoporosis and SREs in neoplastic disease
Osteoporosis and SREs in neoplastic disease

Eugene V. McCloskey

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 20 January 2021

In patients with bone metastases, increased osteoclastic bone resorption contributes to skeletal complications and has led to the use of anti-resorptive therapies in routine clinical management.

Bisphosphonates and denosumab are effective in preventing treatment-induced bone loss and reducing skeletal complications in metastatic disease.

Current hormonal management of breast or prostate cancer is associated with bone loss and an increased risk of osteoporotic fracture. The risk of fracture and bone protection should be considered.

Anti-resorptive therapy can play a role in prevention of bone metastases in early breast cancer in post-menopausal women.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.